Inventor · disambiguated record
Karin Jooss
Also filed as: JOOSS KARIN · JOOSS KARIN UTE
28 granted patents·57 pending applications·361 citations·filing 2002–2025
96Inventor score
Files withGRITSTONE BIO INC39BIOSANTE PHARMACEUTICALS INC9CELL GENESYS INC8PFIZER7GRITSTONE ONCOLOGY INC4
Top patents by PatentIndex Score
85 records- 0197US8580247B2PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereofLI BETTY·Filed 2012·Granted Nov 12, 2013·54 cites·19 claims
- 0297US8287856B2PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereofLI BETTY·Filed 2010·Granted Oct 16, 2012·80 cites·18 claims
- 0394US7498024B2Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage siteCELL GENESYS INC·Filed 2004·Granted Mar 3, 2009·32 cites·28 claims
- 0493US7919079B2Cancer immunotherapy compositions and methods of useBIOSANTE PHARMACEUTICALS INC·Filed 2007·Granted Apr 5, 2011·16 cites·28 claims
- 0592US7714119B2AAV vector compositions and methods for enhanced expression of immunoglobulins using the sameBIOSANTE PHARMACEUTICALS INC·Filed 2005·Granted May 11, 2010·15 cites·17 claims
- 0692US7485291B2Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereofCELL GENESYS INC·Filed 2003·Granted Feb 3, 2009·33 cites·20 claims
- 0791US7662623B2Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage siteBIOSANTE PHARMACEUTICALS INC·Filed 2007·Granted Feb 16, 2010·14 cites·6 claims
- 0889US12109257B2Alphavirus neoantigen vectorsGRITSTONE BIO INC·Filed 2022·Granted Oct 8, 2024·1 cites·20 claims
- 0989US11591619B2Modified adenovirusesGRITSTONE BIO INC·Filed 2021·Granted Feb 28, 2023·1 cites·41 claims
- 1089US7709224B2Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage siteBIOSANTE PHARMACEUTICALS INC·Filed 2004·Granted May 4, 2010·19 cites·7 claims
- 1189US7186699B2Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genesCELL GENESYS INC·Filed 2004·Granted Mar 6, 2007·52 cites·15 claims
- 1288US11771747B2Multiepitope vaccine cassettesGRITSTONE BIO INC·Filed 2022·Granted Oct 3, 2023·2 cites·23 claims
- 1388US11510973B2Alphavirus antigen vectorsGRITSTONE BIO INC·Filed 2022·Granted Nov 29, 2022·1 cites·57 claims
- 1486US8425897B2Compositions containing LAG-3 and cells that secrete GM-CSF and methods of useJOOSS KARIN·Filed 2008·Granted Apr 23, 2013·5 cites·6 claims
- 1585US10660953B2Anti-PD-1 antibodies and methods of use thereofRINAT NEUROSCIENCE CORP·Filed 2018·Granted May 26, 2020·2 cites·19 claims
- 1685US9468672B2Prostate-associated antigens and vaccine-based immunotherapy regimensPFIZER·Filed 2015·Granted Oct 18, 2016·6 cites·20 claims
- 1784US8840881B2Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancerJOOSS KARIN·Filed 2009·Granted Sep 23, 2014·6 cites·9 claims
- 1883US9066898B2Prostate-associated antigens and vaccine-based immunotherapy regimensPFIZER·Filed 2013·Granted Jun 30, 2015·6 cites·13 claims
- 1983US7901902B2Methods and compositions for identifying a cellular immune response against prostate cancerBIOSANTE PHARMACEUTICALS INC·Filed 2007·Granted Mar 8, 2011·3 cites·19 claims
- 2083US7632509B2Methods to express recombinant proteins from lentiviral vectorsBIOSANTE PHARMACEUTICALS INC·Filed 2006·Granted Dec 15, 2009·7 cites·16 claims
- 2183US2025249084A1Alphavirus antigen vectorsGRITSTONE BIO INC·Filed 2024·Application pending·0 cites
- 2280US11504421B2Alphavirus neoantigen vectorsGRITSTONE BIO INC·Filed 2018·Granted Nov 22, 2022·1 cites·30 claims
- 2379US12098383B2Modified adenovirusesGRITSTONE BIO INC·Filed 2023·Granted Sep 24, 2024·0 cites·35 claims
- 2479US2025236884A1Modified adenovirusesGRITSTONE BIO INC·Filed 2024·Application pending·0 cites
- 2577US7939271B2Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancerBIOSANTE PHARMACEUTICALS INC·Filed 2008·Granted May 10, 2011·4 cites·57 claims
- 2676US2022249657A1Anti-pd-1 antibodies and methods of use thereofRINAT NEUROSCIENCE CORP·Filed 2022·Application pending·0 cites
- 2775US11110158B2Prostate-associated antigens and vaccine-based immunotherapy regimensPFIZER·Filed 2018·Granted Sep 7, 2021·1 cites·17 claims
- 2875US2009028857A1Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereofCELL GENESYS INC·Filed 2008·Application pending·0 cites
- 2971US2025108105A1Self-amplifying rna compositions and methods of use thereofGRITSTONE BIO INC·Filed 2024·Application pending·0 cites
- 3071US2024067985A1Viral delivery of neoantigensGRITSTONE BIO INC·Filed 2023·Application pending·0 cites
- 3170US11338035B2Anti-PD-1 antibodies and methods of use thereofRINAT NEUROSCIENCE CORP·Filed 2020·Granted May 24, 2022·0 cites·15 claims
- 3270US2014271684A1Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereofMEDAREX INC·Filed 2013·Application pending·0 cites
- 3370US2010151523A1Regulated expression of recombinant proteins from adeno-associated viral vectorsCELL GENESYS INC·Filed 2009·Application pending·0 cites
- 3469US2025353914A1Antigen-binding proteins and related methods of useGRITSTONE BIO INC·Filed 2025·Application pending·0 cites
- 3569US2025025544A1Immune checkpoint inhibitor co-expression vectorsGRITSTONE BIO INC·Filed 2024·Application pending·0 cites
- 3669US2023128001A1Hiv antigens and mhc complexesGRITSTONE BIO INC·Filed 2022·Application pending·0 cites
- 3769US2025255946A1Low-dose neoantigen vaccine therapyGRITSTONE BIO INC·Filed 2024·Application pending·0 cites
- 3868US2024216501A1Neoantigen adjuvant and maintenance therapyGRITSTONE BIO INC·Filed 2024·Application pending·0 cites
- 3968US2023382997A1Antigen-binding proteins targeting shared antigensGRITSTONE BIO INC·Filed 2022·Application pending·0 cites
- 4068US2025270589A1Viral delivery of neoantigensSEATTLE PROJECT CORP·Filed 2025·Application pending·0 cites
- 4167US2024285739A1Multiepitope vaccine cassettesGRITSTONE BIO INC·Filed 2023·Application pending·0 cites
- 4267US2024279343A1Multi-specific antibodies and methods of useGRITSTONE BIO INC·Filed 2023·Application pending·0 cites
- 4365US2023295305A1Antigen-binding proteins and related methods of useGRITSTONE BIO INC·Filed 2023·Application pending·0 cites
- 4464US11058753B2Cancer vaccinesPFIZER·Filed 2019·Granted Jul 13, 2021·0 cites·38 claims
- 4563US2024238412A1Pancoronavirus vaccinesGRITSTONE BIO INC·Filed 2024·Application pending·0 cites
- 4662US2022265812A1Hiv antigens and mhc complexesGRITSTONE BIO INC·Filed 2021·Application pending·0 cites
- 4761US9669081B2Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancerADURO GVAX INC·Filed 2014·Granted Jun 6, 2017·0 cites·6 claims
- 4861US2023287128A1Antigen-binding proteins targeting kklc-1 shared antigenGRITSTONE BIO INC·Filed 2022·Application pending·0 cites
- 4961US2005002916A1Cytokine-expressing cellular vaccine combinationsFiled 2004·Application pending·0 cites
- 5061US2022323558A1Cancer vaccinesPFIZER·Filed 2021·Application pending·0 cites
Showing the top 50 of 85 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Karin Jooss files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →